share_log

10-K: FY2024 Annual Report

10-K: FY2024 Annual Report

10-K：2024財年年報
美股SEC公告 ·  2024/07/29 16:05

Moomoo AI 已提取核心訊息

Heart Test Laboratories reported FY2024 financial results with revenue increasing to $19,000 from $5,000 in FY2023. The company recorded a net loss of $6.6 million compared to $6.4 million in the previous year. Research and development expenses rose 17% to $2.9 million, primarily due to cloud platform development and FDA submission preparation costs.The company made significant strategic progress, entering into multiple license agreements with Mount Sinai in September 2023 to commercialize AI-ECG algorithms. HeartSciences is preparing for FDA 510(k) submission of its MyoVista wavECG device in Q1 2025, following FDA confirmation of the submission pathway in December 2023. The company also launched its MyoVista Insights Cloud Platform development for hosting AI-ECG algorithms.As of April 30, 2024, HeartSciences had $5.8 million in cash, up from $1.7 million the previous year, strengthened by successful capital raises through ATM facilities and equity lines. The company secured key patents in Europe, Canada and India for its ECG technology, while implementing a 1-for-100 reverse stock split in May 2024 to maintain Nasdaq listing compliance.
Heart Test Laboratories reported FY2024 financial results with revenue increasing to $19,000 from $5,000 in FY2023. The company recorded a net loss of $6.6 million compared to $6.4 million in the previous year. Research and development expenses rose 17% to $2.9 million, primarily due to cloud platform development and FDA submission preparation costs.The company made significant strategic progress, entering into multiple license agreements with Mount Sinai in September 2023 to commercialize AI-ECG algorithms. HeartSciences is preparing for FDA 510(k) submission of its MyoVista wavECG device in Q1 2025, following FDA confirmation of the submission pathway in December 2023. The company also launched its MyoVista Insights Cloud Platform development for hosting AI-ECG algorithms.As of April 30, 2024, HeartSciences had $5.8 million in cash, up from $1.7 million the previous year, strengthened by successful capital raises through ATM facilities and equity lines. The company secured key patents in Europe, Canada and India for its ECG technology, while implementing a 1-for-100 reverse stock split in May 2024 to maintain Nasdaq listing compliance.
心臟測試實驗室公佈了2024財年的財務結果，營業收入從2023財年的5000美元增加至19000美元。公司記錄了660萬美元的淨虧損，相比之下，去年爲640萬美元。研發費用增長了17%，達到290萬美元，主要是由於雲平台開發和FDA提交準備成本。公司在戰略上取得了顯著進展，在2023年9月與西奈山醫院簽訂了多項許可協議，以商業化人工智能心電圖算法。HeartSciences正在爲其MyoVista wavECG設備的FDA 510(k)提交做準備，預計在2025年第一季度進行，FDA在2023年12月確認了提交途徑。公司還啓動了MyoVista Insights雲平台的開發，以託管人工智能心電...展開全部
心臟測試實驗室公佈了2024財年的財務結果，營業收入從2023財年的5000美元增加至19000美元。公司記錄了660萬美元的淨虧損，相比之下，去年爲640萬美元。研發費用增長了17%，達到290萬美元，主要是由於雲平台開發和FDA提交準備成本。公司在戰略上取得了顯著進展，在2023年9月與西奈山醫院簽訂了多項許可協議，以商業化人工智能心電圖算法。HeartSciences正在爲其MyoVista wavECG設備的FDA 510(k)提交做準備，預計在2025年第一季度進行，FDA在2023年12月確認了提交途徑。公司還啓動了MyoVista Insights雲平台的開發，以託管人工智能心電圖算法。截至2024年4月30日，HeartSciences的現金餘額爲580萬美元，較去年170萬美元有所增長，這得益於通過ATM設施和股權渠道成功融資。公司在歐洲、加拿大和印度爲其心電圖科技獲得了關鍵專利，同時在2024年5月實施了一次性100股換1股的反向股票拆分，以維持納斯達克上市合規性。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

獨立文件9  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    PAVmed
    PAVMZ
    -- 0.0129
    QT Imaging
    QTI
    -- 0.469
    Sera Prognostics
    SERA
    -- 8.320
    Pacific Biosciences of California
    PACB
    -- 2.100
    Quipt Home Medical
    QIPT
    -- 3.090

    解鎖榜首股票

    熱門討論
    特朗普2.0時代倒計時！全球股市的下一個風口？
    特朗普即將重返政治舞台！他提出的“美國優先”關稅政策、加密貨幣政策以及對科技行業的影響，已成為市場關注的焦點。在此背景下，加密貨幣、特斯拉、AI板塊的未來走勢值得關注。 🎙️️討論： 1. 加密貨幣政策能否利好crypto? 2. 關稅政策能否利好中概等海外資產？ 展开
    賣盤分析師 - 川普的第一天
    查看更多